HC Wainwright reaffirmed their buy rating on shares of Targacept Inc. (NASDAQ:CBIO) in a report published on Thursday. The firm currently has a $3.50 price target on the biopharmaceutical company’s stock.

Separately, Rodman & Renshaw began coverage on shares of Targacept in a research report on Thursday, June 30th. They issued a buy rating and a $3.50 price objective for the company.

Targacept (NASDAQ:CBIO) traded down 4.24% during mid-day trading on Thursday, hitting $1.13. The company had a trading volume of 34,395 shares. The firm’s market capitalization is $13.37 million. The company has a 50 day moving average of $1.25 and a 200 day moving average of $1.44. Targacept has a 1-year low of $1.11 and a 1-year high of $6.04.

Targacept (NASDAQ:CBIO) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by $0.11. Targacept had a negative return on equity of 62.53% and a negative net margin of 4,155.13%. Analysts predict that Targacept will post ($1.40) earnings per share for the current fiscal year.

Targacept Company Profile

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

5 Day Chart for NASDAQ:CBIO

Receive News & Stock Ratings for Targacept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Targacept Inc. and related stocks with our FREE daily email newsletter.